Trial Profile
Continuous administration trial of Phase2 Study of OTS102 in Combination With Gemcitabine in Patients With Unresectable Advanced Biliary Tract Cancer and recurrent Biliary Tract Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 May 2016
Price :
$35
*
At a glance
- Drugs Elpamotide (Primary) ; Gemcitabine
- Indications Biliary cancer
- Focus Therapeutic Use
- Sponsors OncoTherapy Science
- 26 Jul 2012 Planned end date (Dec 2012) added as reported by University Hospital Medical Information Network - Japan record.
- 16 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 04 Oct 2011 New trial record